Howard E. Davis, Ph.D. Email & Phone Number

Abingdon, Oxfordshire, Gb

Served as COO for a clinical stage immunology-focused NewCo founded by Atlas Venture. Joined as employee #4 and took on a critical executive leadership role during the seed-stage of the company. Key responsibilities included fundraising (including closing of $155mn in private financing), sell-side & buy-side business development and leadership of a wide-array of functional activities including new product planning, finance, legal, intellectual property, human resources, and IT.

Served as Head of Corporate Development for a clinical stage neuropsychiatry NewCo founded by Atlas Venture. Joined as employee #2 and took on a key operational and strategic leadership role during the founding and launch of the company. Key responsibilities included fundraising, sell-side & buy-side business development, and functional leadership of finance, legal, intellectual property, human resources, and IT.

Served as a Principal for Flagship Pioneering - a firm focused on the conception, creation, capitalization, and growth of first-in-category life science companies. Accountable for the on-going management and expansion of Flagship Pioneering's portfolio of strategic corporate partnerships with leading pharmaceutical and biotechnology companies. Responsibilities included securing capital commitments from corporate partners, channeling corporate partner input into the Flagship company creation process, and facilitating business development between corporate partners and the Flagship portfolio of companies.

Cambridge, Ma, Us

Corporate general manager for the extracellular tau monoclonal antibody (BIIB092 / BMS-986168) in-licensed from BMS in April 2017 for development in Alzheimer's disease and progressive supranuclear palsy. Accountable for development of the BIIB092 asset strategy and tactical execution across all corporate functions including clinical development, medical affairs, marketing & sales, market access, manufacturing and supply chain. Responsible for overall management of the asset's quarterly P&L, as well as for shaping the asset's long-range financial trajectory to maximize value creation for Biogen.

Cambridge, Ma, Us

Served as a director for Biogen's philanthropic foundation whose mission is to enhance the quality of life and vitality of the communities in which the company operates. The Foundation pursues this mission with a special emphasis on innovative ways to promote science literacy and encourage young people to consider scientific careers. The Board of Directors manages an ~$10 mn annual operating budget to support the Foundation's portfolio of initiatives.

Cambridge, Ma, Us

Accountable for all Pharmaceutical Operations & Technology (PO&T) aspects of the specialty medicines portfolio covering CMC, manufacturing, supply chain & lifecycle management. Approve and execute long-range operational plans for specialty pipeline and in-market assets which generate >$10bn of annual revenue with a focus on COGS management, security of supply, and regulatory CMC strategy. Lead sponsor for patient-centric innovation projects to identify device and/or formulation life cycle management opportunities to enhance each product’s value proposition to patients, physicians & payors.

Cambridge, Ma, Us

[High Potential Development Role]Provided strategic and operational support for the Biogen CEO in the development and execution of his corporate change agenda. Served as the CEO's trusted advisor and confidante with responsibility for leading his priority special projects and key corporate initiatives. Enhanced CEO, executive team, and board of directors effectiveness via proactive management of key leadership forums and meetings.

Cambridge, Ma, Us

Served as the multiple sclerosis (MS) franchise global marketing lead covering both in-line (Tecfidera, Plegridy, Avonex, Tysabri, & Fampyra) and pipeline assets. Led the MS Franchise global marketing team and cross-functional leadership team in the launch of internal and external Biogen MS branding campaigns. Successfully rolled-out Biogen’s first integrated MS Franchise Strategy defining product positioning, physician & patient targeting, and sales rep prioritization across the in-line brands. Delivered a doubling of worldwide MS Franchise sales to $8.0bn (’14) vs. $4.1bn (’12) (+40% CAGR) via harmonization of Tecfidera launch planning and legacy in-line brand strategies.

Basel, Baselstadt, Ch

Served as the global commercial lead for Lucentis, Novartis’ multi-blockbuster medical retina therapy for the treatment of neovascular disorders of the eye. Led a global marketing team and cross-functional leadership team with oversight of a $10mn promotional and medical communication budget. Delivered 17% YoY growth of Lucentis sales to $2.4bn (ex-US) in 2012 driven by strong execution in the legacy indication (wet age-related macular degeneration) and successful new indication launches (diabetic macular edema and retinal vein occlusion).

Basel, Baselstadt, Ch

Served as a member of the global multiple sclerosis (MS) marketing team supporting the worldwide launch of Novartis’ first MS product, Extavia, as well as launch preparations for Gilenya. Responsibilities included leadership of a cross-functional team accountable for brand positioning, launch planning, medical communications, pricing & market access, and lifecycle management. Delivered Extavia worldwide launch year sales of $49mn ('09) growing to $154mn (’11).

Basel, Baselstadt, Ch

Served as a member of the strategic planning team for the company's largest operating division (Novartis Pharma) with responsibility for critical annual planning processes (e.g., long-range plan, disease area strategy), as well as special projects and organizational initiatives sponsored by the CEO. Served as strategic lead for a cross-functional M&A team focused on the screening and due diligence of large cap targets whose work paved the way for Novartis' $50bn acquisition of Alcon, Inc. (the largest acquisition in Swiss history).

Boston, Massachusetts, Us

Project Leader (Aug. 2006 - June 2007)Consultant (Aug. 2004 - July 2006)Served as a management consultant to senior executives of Fortune 100 pharmaceutical and biotechnology companies with casework focused on corporate strategy, R&D portfolio management, and organizational transformation. Following promotion to project leader, led teams of 3-5 consultants in the work planning, execution and delivery of client projects.

Boston, Ma, Us

Served as a key leader in the Global Competitiveness life science practice during a period of rapid expansion of the client base and business revenues. Key responsibilities included new business development, client management, and oversight of 3-5 member project teams providing intellectual property consulting support for our clients' business development, M&A, and portfolio lifecycle management activities. Clients included Fortune 500 large pharma, biotechnology, and medical device companies.

Ph.D., Biomedical Engineering

B.S., Chemical Engineering